Results 31 to 40 of about 110,630 (313)

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations [PDF]

New England Journal of Medicine, 2012
Resistance to therapy with BRAF kinase inhibitors is associated with reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selective MAPK kinase (MEK) inhibitor.In this open-label study ...
Flaherty, Keith T, Infante, Jeffery R, Daud, Adil, Gonzalez, Rene, Kefford, Richard F, Sosman, Jeffrey, Hamid, Omid, Schuchter, Lynn, Cebon, Jonathan, Ibrahim, Nageatte, Kudchadkar, Ragini, Burris, Howard A, Falchook, Gerald, Algazi, Alain, Lewis, Karl, Long, Georgina V, Puzanov, Igor, Lebowitz, Peter, Singh, Ajay, Little, Shonda, Sun, Peng, Allred, Alicia, Ouellet, Daniele, Kim, Kevin B, Patel, Kiran, Weber, Jeffrey   +25 more
openaire   +4 more sources

BRAF V600E mutáció vizsgálata hajas sejtes leukémiában [PDF]

, 2021
Kutatási munkám célja a BRAF gén V600E mutáció kimutatásának beállítása HRM módszer alkalmazásával. A mutáció kimutatására több módszer is alkalmas, Sanger szekvenálás, allélspecifikus PCR vagy nagy felbontású olvadáspont-analízis.
Kazamér, Barbara
core  

Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient

Cancer Biology & Therapy, 2023
The treatment of BRAFV600E mutant melanoma has been revolutionized by BRAF inhibitors. Furthermore, the BRAF/MEK combination has shown further improvement in clinical outcomes in advanced and in adjuvant melanoma patients.
Sandro Anchisi, Anita Wolfer, Bettina Bisig, Edoardo Missiglia, Amine Tiab, Ehab Mohamed Kamel, Olivier Michielin, George Coukos, Krisztian Homicsko   +8 more
doaj   +1 more source

KRAS mutation analysis by PCR : a comparison of two methods [PDF]

, 2015
Background: KRAS mutation assays are important companion diagnostic tests to guide anti-EGFR antibody treatment of metastatic colorectal cancer. Direct comparison of newer diagnostic methods with existing methods is an important part of validation of ...
Lucas, Katie, Anne Reiman, Reiman, Anne, Louise Bolton, Timms, Judith, Katie Lucas, Ian A Cree, Bolton, Louise, Cree, Ian A., Judith Timms   +9 more
core   +1 more source

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma [PDF]

Molecular & Cellular Oncology, 2015
Recent analyses by our group and others showed that the majority of melanoma patients who fail BRAF inhibitor therapy do so at new disease sites. Using phosphoproteomics we showed that BRAF inhibition mediates a switch to an aggressive/metastatic melanoma phenotype that is driven by ligand-independent erythropoietin-producing hepatocellular receptor A2
Smalley, Keiran SM, Fedorenko, Inna V
openaire   +2 more sources

BRAF mutations in low-grade serous ovarian cancer and response to BRAF inhibition [PDF]

, 2018
© 2019 American Society of Clinical Oncology. Purpose Low-grade serous ovarian carcinoma (LGSC) responds poorly to chemotherapy and is characterized by activating mutations in the Ras sarcoma-mitogen-activated protein kinase (RAS-MAPK) pathway, including
Wain, GV, Kennedy, CJ, Saunders, C, Balleine, RL, Gao, B, Hogg, R, Kan, C, Traficante, N, Etemadmoghadam, D, Srirangan, S, Hung, J, Fereday, S, Chiew, YE, Moujaber, T, et al.   +14 more
core   +1 more source

V600e braf inhibition induces cytoprotective autophagy through ampk in thyroid cancer cells [PDF]

, 2021
The dysregulation of autophagy is important in the development of many cancers, including thyroid cancer, whereV600E BRAF is a main oncogene. Here, we analyse the effect ofV600E BRAF inhibition on autophagy, the mechanisms involved in this regulation and
Díaz-Gago, Sergio, Lasa Benito, Marina Paloma, Díaz Gago, Sergio, Lasa, Marina, Marina Lasa, Gallego, Beatriz, Chiloeches, Antonio, Baquero Valls, Pablo, Sergio Díaz-Gago, Gallego Tamayo, Beatriz, Antonio Chiloeches, Chiloeches Gálvez, Antonio, Beatriz Gallego, Jiménez-Mora, Eva, Baquero, Pablo, Jiménez Mora, Eva María, Eva Jiménez-Mora, Pablo Baquero   +17 more
core   +1 more source

KRAS and BRAF Concomitant Mutations in a Patient with Metastatic Colon Adenocarcinoma: An Interesting Case Report

Case Reports in Oncology, 2020
A 68-year-old female patient with tenesmus and blood in the stool was admitted to the S.G. Moscati Hospital of Taranto. Investigations revealed infiltrative mucinous colon adenocarcinoma accompanied by lymph node metastases.
Concetta Cafiero, Agnese Re, Gerardo D’Amato, Pier Luigi Surico, Giammarco Surico, Michele Pirrelli, Salvatore Pisconti   +6 more
doaj   +1 more source

ToBRAFor Not toBRAF: Is That Even a Question Anymore? [PDF]

Journal of Neuropathology & Experimental Neurology, 2013
Alterations in BRAF have been discovered in most pediatric low-grade gliomas. Because the field has moved quickly during the past few years, there is not yet widespread awareness about what B-Raf normally does, how the BRAF gene is modified in gliomas, why mutant proteins promote gliomagenesis, and what an abnormal BRAF result means for diagnosis ...
openaire   +2 more sources

Prevalence of BRAF and NRAS mutations in cutaneous melanoma patients in Taiwan [PDF]

, 2017
Background/Purpose: BRAF and NRAS mutations have been described in melanomas among Caucasians and some Asian populations. However, few large-scale studies have investigated the status and clinical significance of BRAF and NRAS mutations in a Taiwanese ...
紀秀華;廖怡華;朱家瑜;廖肇裕;沈宜萱, Sheen, Yi-Shuan;Liao, Yi-Hua;Liau, Jau-Yu;Lin, Ming-Hsien;Hsieh, Yi-Chun;Jee, Shiou-Hwa;Chu, Chia-Yu   +1 more
core   +1 more source